

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human ATBF1/ZFHX3 in direct ELISAs.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant human ATBF1/ZFHX3 His3608-Leu3703 Accession # Q15911
Conjugate	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Immunocytochemistry Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

ATBF1 (Adenine-Thymine motif Binding Factor 1; also ZFHX3) is a 400 kDa highly modular protein that contains motifs found in multiple transcription factor families. It is expressed by a variety of cells, both normal and malignant, including postmitotic neurons, hepatocytes, mammary epithelium and gastric carcinoma cells. ATBF1 is both cytoplasmic and nuclear, and its localization has pronounced effects on the cell cycle. Cytoplasmic ATBF1 is associated with cell proliferation, while nuclear ATBF1 appears to promote cell differentiation. Human ATBF1-A is 3703 amino acids (aa) in length. It contains seventeen consecutive C2H2-type Zn finger domains interspersed with short poly-Glu and poly-Ala segments (aa 282-2006), followed by two homeobox domains (aa 2146-2301), two additional C2H2 Zn finger domains (aa 2328-2552) and two homeobox plus three intermixed Zn finger domains. There are at least six utilized Ser phosphorylation sites. Two isoform variants have been reported. The first is termed ATBF1-B. It has a predicted MW of 306 kDa and appears following the use of an alternative start site at Met915. When the 914 aa N-terminus is present (as in ATBF1-A), ATBF1 shows transcriptional repression; when it is absent (as in ATBF1-B), ATBF1 acts as a transcriptional activator. The second isoform variant contains a 41 aa substitution for aa 1150-3703. Over aa 3608-3703, human ATBF1 shares 98% aa sequence identity with mouse ATBF1.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.